The Colon/Rectal Cancer Panel from National Cancer Comprehensive Network (NCCN) recently revised its guideline (Version 2.2016) for anti-EFGR therapy by recommending genotyping of tumor tissues in all patients with metastatic CRC for the extended RAS mutations as well as BRAF mutations (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp). This evidence concerns the gene BRAF and neoplasm.